Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
- Published In:
- Lancet (London, England), 402(10403), 720-730 (2023)
- Authors:
- Frias, Juan P(5), Deenadayalan, Srikanth, Erichsen, Lars, Knop, Filip K, Lingvay, Ildiko, Macura, Stanislava, Mathieu, Chantal, Pedersen, Sue D, Davies, Melanie
- Database ID:
- RPEP-06885
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06885APA
Frias, Juan P; Deenadayalan, Srikanth; Erichsen, Lars; Knop, Filip K; Lingvay, Ildiko; Macura, Stanislava; Mathieu, Chantal; Pedersen, Sue D; Davies, Melanie. (2023). Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.. Lancet (London, England), 402(10403), 720-730. https://doi.org/10.1016/S0140-6736(23)01163-7
MLA
Frias, Juan P, et al. "Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.." Lancet (London, 2023. https://doi.org/10.1016/S0140-6736(23)01163-7
RethinkPeptides
RethinkPeptides Research Database. "Efficacy and safety of co-administered once-weekly cagrilint..." RPEP-06885. Retrieved from https://rethinkpeptides.com/research/frias-2023-efficacy-and-safety-of-2
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.